Logo

Ipsogen to Offer Affymetrix-Based Research Services

Jul 23, 2004

NEW YORK, July 23 (GenomeWeb News) - Ipsogen will provide microarray-based services to industrial and academic customers based on Affymetrix's technology, the Marseille, France-based company said today.

 

As an "authorized service provider" for Affymetrix technology, Ipsogen will add Affymetrix's GeneChip system to its research services. The company's services focus on the molecular diagnosis of cancer and the discovery and development of anti-cancer drugs.

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.